Chemoinformaics analysis of 1,2-ANHYDRIDO-4,5-DIHYDO-NIVEUSIN-A
| Molecular Weight | 378.421 | nRot | 3 |
| Heavy Atom Molecular Weight | 352.213 | nRig | 19 |
| Exact Molecular Weight | 378.168 | nRing | 2 |
| Solubility: LogS | -1.331 | nHRing | 1 |
| Solubility: LogP | 0.337 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 53 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 27 | No. of Aromatic Carbocycles | 0 |
| nHetero | 7 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 26 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 20 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 7 | No. of Arom Bond | 0 |
| nHA | 7 | APOL | 56.3506 |
| nHD | 2 | BPOL | 32.1594 |
| QED | 0.561 |
| Synth | 5.211 |
| Natural Product Likeliness | 3.317 |
| NR-PPAR-gamma | 0.893 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.841 |
| Pgp-sub | 0 |
| HIA | 0.308 |
| CACO-2 | -4.816 |
| MDCK | 0.0000133 |
| BBB | 0.688 |
| PPB | 0.601042 |
| VDSS | 0.453 |
| FU | 0.234181 |
| CYP1A2-inh | 0.021 |
| CYP1A2-sub | 0.12 |
| CYP2c19-inh | 0.115 |
| CYP2c19-sub | 0.733 |
| CYP2c9-inh | 0.124 |
| CYP2c9-sub | 0.109 |
| CYP2d6-inh | 0.074 |
| CYP2d6-sub | 0.051 |
| CYP3a4-inh | 0.846 |
| CYP3a4-sub | 0.399 |
| CL | 8.137 |
| T12 | 0.772 |
| hERG | 0.021 |
| Ames | 0.011 |
| ROA | 0.605 |
| SkinSen | 0.758 |
| Carcinogencity | 0.876 |
| EI | 0.051 |
| Respiratory | 0.765 |
| NR-Aromatase | 0.624 |
| Antiviral | Yes |
| Prediction | 0.627474 |